Home » Newsletters » BioWorld

BioWorld

Oct. 5, 2000

View Archived Issues

Zarix Raises $23.5M In Series C For Phase III Pivotal Of Thymitaq

Appointments And Advancements

Other News To Note

MethylGene Raises $18.6M For Drug Discovery, Development

Neurocrine Seeks $115M Publicly Through Offering Of 3M Shares

Id Gene, Key Co-Conspirator Of Neuroblastoma - With Rb, Myc - Yields To Prospective Inhibitor

Isis Decides To Move 2302 Into Phase III After Revisiting Data

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 17, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
Mechanism underlying so-called idiopathic autism inception unveiled
BioWorld Science
Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.